Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ecopipam Treatment of Tourette Syndrome.

Next Previous
Trial Profile

Ecopipam Treatment of Tourette Syndrome.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ecopipam (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Sponsors Psyadon Pharmaceuticals

Most Recent Events

  • 28 Sep 2015 Status changed from discontinued to completed as per ClinicalTrials.gov record.
  • 24 Jul 2012 Positive interim results from the phase II portion of this trial have been presented in a Psyadon Pharmaceuticals media release.
  • 24 Jul 2012 Status changed from recruiting to discontinued (terminated early), according to a Psyadon Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top